Neural Organoids Protect Engineered Heart Tissues From Glucolipotoxicity by Transferring Versican in a Co-Culture System

Abstract

Metabolic disorders could cause dysregulated glucose and lipid at the systemic level, but how inter-tissue/organ communications contribute to glucolipotoxicity is difficult to dissect in animal models. To solve this problem, myocardium and nerve tissues were modelled by 3D engineered heart tissues (EHTs) and neural organoids (NOs), which were co-cultured in a generalised medium with normal or elevated glucose/fatty acid contents. Morphology, gene expression, cell death and functional assessments detected no apparent alterations of EHTs and NOs in co-culture under normal conditions. By contrast, NOs significantly ameliorated glucolipotoxicity in EHTs. Transcriptomic and protein secretion assays identified the extracellular matrix protein versican as a key molecule that was transferred from NOs into EHTs in the high-glucose/fatty acid condition. Recombinant versican protein treatment was sufficient to reduce glucolipotoxicity in EHTs. Adeno-associated virus-delivered versican overexpression was sufficient to ameliorate cardiac dysfunction in a murine model of diabetic cardiomyopathy. These data provide the proof-of-concept evidence that inter-tissue/organ communications exist in the co-culture of engineered tissues and organoids, which could be systemically studied to explore potential pathological mechanisms and therapeutic strategies for multi-organ diseases in vitro.

Keywords

engineered heart tissues / glucolipotoxicity / neural organoids / versican

References

[1] V. Poitout and R. P. Robertson, “Glucolipotoxicity: Fuel Excess and Beta-Cell Dysfunction,” Endocrine Reviews 29, no. 3 (2008): 351–366.

[2] R. H. Ritchie and E. D. Abel, “Basic Mechanisms of Diabetic Heart Disease,” Circulation Research 126, no. 11 (2020): 1501–1525.

[3] P. M. Seferović, W. J. Paulus, G. Rosano, et al., “Diabetic Myocardial Disorder. A Clinical Consensus Statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases,” European Journal of Heart Failure 26, no. 9 (2024): 1893–1903.

[4] W. Kosmala, P. Sanders, and T. H. Marwick, “Subclinical Myocardial Impairment in Metabolic Diseases,” JACC: Cardiovascular Imaging 10, no. 6 (2017): 692–703.

[5] E. L. Feldman, B. C. Callaghan, R. Pop-Busui, et al., “Diabetic Neuropathy,” Nature Reviews Disease Primers 5, no. 1 (2019): 42.

[6] E. L. Feldman, K. A. Nave, T. S. Jensen, and D. L. H. Bennett, “New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain,” Neuron 93, no. 6 (2017): 1296–1313.

[7] T. T. van Sloten, S. Sedaghat, M. R. Carnethon, L. J. Launer, and C. D. A. Stehouwer, “Cerebral Microvascular Complications of Type 2 Diabetes: Stroke, Cognitive Dysfunction, and Depression,” Lancet Diabetes and Endocrinology 8, no. 4 (2020): 325–336.

[8] J. B. Cole and J. C. Florez, “Genetics of Diabetes Mellitus and Diabetes Complications,” Nature Reviews. Nephrology 16, no. 7 (2020): 377–390.

[9] H. Zhao, Y. Cheng, J. Li, et al., “Droplet-Engineered Organoids Recapitulate Parental Tissue Transcriptome With Inter-Organoid Homogeneity and Inter-Tumor Cell Heterogeneity,” Fundamental Research 4, no. 6 (2024): 1506–1514.

[10] J. A. Bagley, D. Reumann, S. Bian, J. Lévi-Strauss, and J. A. Knoblich, “Fused Cerebral Organoids Model Interactions Between Brain Regions,” Nature Methods 14, no. 7 (2017): 743–751.

[11] L. Magré, M. M. A. Verstegen, S. Buschow, L. J. W. van der Laan, M. Peppelenbosch, and J. Desai, “Emerging Organoid-Immune Co-Culture Models for Cancer Research: From Oncoimmunology to Personalized Immunotherapies,” Journal for Immunotherapy of Cancer 11, no. 5 (2023): e006290.

[12] D. Zink, J. K. C. Chuah, and J. Y. Ying, “Assessing Toxicity With Human Cell-Based in Vitro Methods,” Trends in Molecular Medicine 26, no. 6 (2020): 570–582.

[13] P. Mu, S. Zhou, T. Lv, et al., “Newly Developed 3D In Vitro Models to Study Tumor-Immune Interaction,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 81.

[14] J. Lee, D. Gil, H. Park, et al., “A Multicellular Liver Organoid Model for Investigating Hepatitis C Virus Infection and Nonalcoholic Fatty Liver Disease Progression,” Hepatology 80, no. 1 (2024): 186–201.

[15] L. Wang, D. Sievert, A. E. Clark, et al., “A Human Three-Dimensional Neural-Perivascular ‘assembloid’ Promotes Astrocytic Development and Enables Modeling of SARS-CoV-2 Neuropathology,” Nature Medicine 27, no. 9 (2021): 1600–1606.

[16] A. J. Crawford, A. Forjaz, J. Bons, et al., “Combined Assembloid Modeling and 3D Whole-Organ Mapping Captures the Microanatomy and Function of the Human Fallopian Tube,” Science Advances 10, no. 39 (2024): eadp6285.

[17] R. M. Marton and S. P. Pașca, “Organoid and Assembloid Technologies for Investigating Cellular Crosstalk in Human Brain Development and Disease,” Trends in Cell Biology 30, no. 2 (2020): 133–143.

[18] J. Li, A. Wiesinger, L. Fokkert, et al., “Modeling the Atrioventricular Conduction Axis Using Human Pluripotent Stem Cell-Derived Cardiac Assembloids,” Cell Stem Cell 31, no. 11 (2024): 1667–1684.e1666.

[19] J. Hao, A. Ma, L. Wang, et al., “General Requirements for Stem Cells,” Cell Proliferation 53, no. 12 (2020): e12926.

[20] J. Hao, J. Cao, L. Wang, et al., “Requirements for Human Embryonic Stem Cells,” Cell Proliferation 53, no. 12 (2020): e12925.

[21] J. A. Thomson, J. Itskovitz-Eldor, S. S. Shapiro, et al., “Embryonic Stem Cell Lines Derived From Human Blastocysts,” Science 282, no. 5391 (1998): 1145–1147.

[22] Y. Huang, Y. Zhang, Z. Wang, et al., “Modified mRNA-Based Gene Editing Reveals Sarcomere-Based Regulation of Gene Expression in Human Induced-Pluripotent Stem Cell-Derived Cardiomyocytes,” International Immunopharmacology 143, no. 2 (2024): 113378.

[23] L. Li, Z. Wan, R. Wang, et al., “Generation of High-Performance Human Cardiomyocytes and Engineered Heart Tissues From Extended Pluripotent Stem Cells,” Cell Discovery 8, no. 1 (2022): 105.

[24] H. Xu, G. Liu, J. Gong, et al., “Investigating and Resolving Cardiotoxicity Induced by COVID-19 Treatments Using Human Pluripotent Stem Cell-Derived Cardiomyocytes and Engineered Heart Tissues,” Advanced Science 9, no. 30 (2022): e2203388.

[25] D. Yin, Y. Liu, B. Xue, et al., “IL-37 Modulates Myocardial Calcium Handling via the p-STAT3/SERCA2a Axis in HF-Related Engineered Human Heart Tissue,” Advanced Healthcare Materials 13, no. 13 (2024): e2303957.

[26] X. Y. Tang, L. Xu, J. Wang, et al., “DSCAM/PAK1 Pathway Suppression Reverses Neurogenesis Deficits in iPSC-Derived Cerebral Organoids From Patients With Down Syndrome,” Journal of Clinical Investigation 131, no. 12 (2021): e135763.

[27] L. Xu, Y. Zhang, X. Chen, et al., “Human Brain Organoids Model Abnormal Prenatal Neural Development Induced by Thermal Stimulation,” Cell Proliferation 58 (2024): e13777.

[28] J. Lin, Z. Chen, L. Yang, et al., “Cas9/AAV9-Mediated Somatic Mutagenesis Uncovered the Cell-Autonomous Role of Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 2 in Murine Cardiomyocyte Maturation,” Frontiers in Cell and Development Biology 10 (2022): 864516.

[29] S. Andrews, “FastQC: A Quality Control Tool for High Throughput Sequence Data,” 2016, http://www.bioinformatics.babraham.ac.uk/projects/fastqc/.

[30] A. M. Bolger, M. Lohse, and B. Usadel, “Trimmomatic: A Flexible Trimmer for Illumina Sequence Data,” Bioinformatics 30, no. 15 (2014): 2114–2120.

[31] A. Dobin, C. A. Davis, F. Schlesinger, et al., “STAR: ultrafast universal RNA-seq aligner,” Bioinformatics 29, no. 1 (2013): 15–21.

[32] Y. Liao, G. K. Smyth, and W. Shi, “featureCounts: An Efficient General Purpose Program for Assigning Sequence Reads to Genomic Features,” Bioinformatics 30, no. 7 (2014): 923–930.

[33] M. I. Love, W. Huber, and S. Anders, “Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data With DESeq2,” Genome Biology 15, no. 12 (2014): 550.

[34] A. Subramanian, P. Tamayo, V. K. Mootha, et al., “Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles,” Proceedings of the National Academy of Sciences of the United States of America 102, no. 43 (2005): 15545–15550.

[35] Y. Sun, C. Guo, Z. Chen, et al., “Non-Cell-Autonomous Cardiomyocyte Regulation Complicates Gene Supplementation Therapy for Lmna-Associated Cardiac Defects in Mice,” JACC: Basic to Translational Science 9, no. 11 (2024): 1308–1325.

[36] Y. Guo, N. J. VanDusen, L. Zhang, et al., “Analysis of Cardiac Myocyte Maturation Using CASAAV, a Platform for Rapid Dissection of Cardiac Myocyte Gene Function in Vivo,” Circulation Research 120, no. 12 (2017): 1874–1888.

[37] Y. Chen-Izu, T. Banyasz, J. A. Shaw, and L. T. Izu, “The Heart Is a Smart Pump: Mechanotransduction Mechanisms of the Frank–Starling Law and the Anrep Effect,” Annual Review of Physiology 87 (2025): 53–77.

[38] P. Hofbauer, S. M. Jahnel, N. Papai, et al., “Cardioids Reveal Self-Organizing Principles of Human Cardiogenesis,” Cell 184, no. 12 (2021): 3299–3317.e3222.

[39] S. Picelli, Å. K. Björklund, O. R. Faridani, S. Sagasser, G. Winberg, and R. Sandberg, “Smart-seq2 for Sensitive Full-Length Transcriptome Profiling in Single Cells,” Nature Methods 10, no. 11 (2013): 1096–1098.

[40] Y. Guo and W. T. Pu, “Cardiomyocyte Maturation: New Phase in Development,” Circulation Research 126, no. 8 (2020): 1086–1106.

[41] D. Smedley, S. Haider, S. Durinck, et al., “The BioMart Community Portal: An Innovative Alternative to Large, Centralized Data Repositories,” Nucleic Acids Research 43, no. W1 (2015): W589–W598.

[42] L. Wang, C. Wang, J. A. Moriano, et al., “Molecular and Cellular Dynamics of the Developing Human Neocortex,” Nature (2025), https://doi.org/10.1038/s41586-024-08351-7.

[43] J. Feng, Y. Li, Y. Li, et al., “Versican Promotes Cardiomyocyte Proliferation and Cardiac Repair,” Circulation 149, no. 13 (2024): 1004–1015.

[44] H. Wang, J. Wang, H. Cui, et al., “Inhibition of Fatty Acid Uptake by TGR5 Prevents Diabetic Cardiomyopathy,” Nature Metabolism 6, no. 6 (2024): 1161–1177.

[45] T. N. Wight, “A Role for Proteoglycans in Vascular Disease,” Matrix Biology 71–72 (2018): 396–420.

[46] N. W. S. Chew, C. H. Ng, D. J. H. Tan, et al., “The Global Burden of Metabolic Disease: Data From 2000 to 2019,” Cell Metabolism 35, no. 3 (2023): 414–428.e413.

[47] H. Tilg, A. R. Moschen, and M. Roden, “NAFLD and diabetes mellitus,” Nature Reviews. Gastroenterology & Hepatology 14, no. 1 (2017): 32–42.

[48] F. R. Li, D. N. Hukportie, J. Yang, H. H. Yang, G. C. Chen, and X. B. Wu, “Microvascular Burden and Incident Heart Failure Among Middle-Aged and Older Adults With Type 1 or Type 2 Diabetes,” Diabetes Care 45, no. 12 (2022): 2999–3006.

[49] W. Pang, J. Zhu, K. Yang, et al., “Generation of Human Region-Specific Brain Organoids With Medullary Spinal Trigeminal Nuclei,” Cell Stem Cell 31, no. 10 (2024): 1501–1512.e1508.

[50] S. K. Mohanta, C. Yin, C. Weber, et al., “Cardiovascular Brain Circuits,” Circulation Research 132, no. 11 (2023): 1546–1565.

[51] I. Durães Campos, V. Pinto, N. Sousa, and V. H. Pereira, “A Brain Within the Heart: A Review on the Intracardiac Nervous System,” Journal of Molecular and Cellular Cardiology 119 (2018): 1–9.

[52] L. Duan and X. Yu, “Fibroblasts: New Players in the Central Nervous System?,” Fundamental Research 4, no. 2 (2024): 262–266.

[53] D. J. Henderson and A. J. Copp, “Versican Expression Is Associated With Chamber Specification, Septation, and Valvulogenesis in the Developing Mouse Heart,” Circulation Research 83, no. 5 (1998): 523–532.

[54] T. J. Mead, S. Bhutada, S. J. Foulcer, et al., “Combined Genetic-Pharmacologic Inactivation of Tightly Linked ADAMTS Proteases in Temporally Specific Windows Uncovers Distinct Roles for Versican Proteolysis and Glypican-6 in Cardiac Development,” Matrix Biology 131 (2024): 1–16.

[55] Z. Q. He, X. W. Yuan, Z. B. Lu, et al., “Pharmacological Regulation of Tissue Fibrosis by Targeting the Mechanical Contraction of Myofibroblasts,” Fundamental Research 2, no. 1 (2022): 37–47.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.